Is Age Just a “Number” When Evaluating the Efficacy and Safety of Triple-Inhaled Therapy in COPD?

Sandra G. Adams; Rodolfo A. Estrada

doi:10.1016/j.chest.2020.10.022

Is Age Just a “Number” When Evaluating the Efficacy and Safety of Triple-Inhaled Therapy in COPD?

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	895-896
Number of pages	2
Journal	Chest
Volume	159
Issue number	3
DOIs	https://doi.org/10.1016/j.chest.2020.10.022
State	Published - Mar 2021
Externally published	Yes

ASJC Scopus subject areas

Critical Care and Intensive Care Medicine
Cardiology and Cardiovascular Medicine
Pulmonary and Respiratory Medicine

Access to Document

10.1016/j.chest.2020.10.022

Cite this

@article{52c0d2d867b946529e5ed175f79689db,

title = "Is Age Just a “Number” When Evaluating the Efficacy and Safety of Triple-Inhaled Therapy in COPD?",

author = "Adams, {Sandra G.} and Estrada, {Rodolfo A.}",

note = "Funding Information: FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the following: S. G. A. reports unrestricted grants for educational research from the following companies: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Mylan/Theravance, and Sunovion. None declared (R. A. E.).",

year = "2021",

month = mar,

doi = "10.1016/j.chest.2020.10.022",

language = "English (US)",

volume = "159",

pages = "895--896",

journal = "Chest",

issn = "0012-3692",